Disease · MONDO_0019082
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52 | 51 of 53 | 51 of 53 | 106 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One Serious TEAE Through Week 52 | 12 of 53 | 16 of 53 | 106 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: deaths from any cause | 2 of 53 | 6 of 53 | 106 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52 | 4 of 53 | 0 of 53 | 106 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: serious adverse events | 20 of 53 | 21 of 53 | 106 | NCT04206553 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36 | 9 of 50 | 3 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CDA Who Remained Free of Relapse Through Week 36 | 7 of 50 | 8 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CRoff at Week 36 | 8 of 50 | 2 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants With CRmin at Week 36 | 8 of 50 | 3 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: Number of Participants Who Receive Rescue Therapy Before Week 36 | 19 of 50 | 18 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: deaths from any cause | 1 of 50 | 2 of 48 | 98 | NCT05267600 | Trial comparisons |
| Efgartigimod PH20 SC vs Placebo PH20 SC: serious adverse events | 12 of 50 | 12 of 48 | 98 | NCT05267600 | Trial comparisons |
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One TEAE Through Week 64 | 25 of 52 | 23 of 44 | 96 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One Serious TEAE Through Week 64 | 8 of 52 | 8 of 44 | 96 | NCT04206553 | Trial comparisons |
| Dupilumab Q2W vs Placebo: Number of Participants With At Least One TE AESI Through Week 64 | 0 of 52 | 0 of 44 | 96 | NCT04206553 | Trial comparisons |
| Mometasone Furoate + AKST4290 vs Mometasone Furoate + Placebo: The Percentage of Subjects Who Achieve Disease Control Without Rescue Therapy | 2 of 5 | 1 of 1 | 6 | NCT04499235 | Trial comparisons |
| Mometasone Furoate + AKST4290 vs Mometasone Furoate + Placebo: deaths from any cause | 0 of 5 | 1 of 1 | 6 | NCT04499235 | Trial comparisons |
| Mometasone Furoate + AKST4290 vs Mometasone Furoate + Placebo: serious adverse events | 0 of 5 | 1 of 1 | 6 | NCT04499235 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019082/comparisons